According to The Fly, in a report released yesterday, Michael Leuchten from UBS maintained a Buy rating on Novo Nordisk (NVO). The company’s shares closed yesterday at $46.62.
Leuchten has an average return of 4.7% when recommending Novo Nordisk.
According to TipRanks.com, Leuchten is ranked #3483 out of 5131 analysts.
Novo Nordisk has an analyst consensus of Moderate Buy.
See today’s analyst top recommended stocks >>
The company has a one-year high of $58.37 and a one-year low of $41.23. Currently, Novo Nordisk has an average volume of 1.57M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following business segments: Diabetes & Obesity Care, and Biopharmaceuticals.
